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Abstract 
In vitro metabolism of the synthetic cannabinoids PX-1, PX-2, PX-3 and a comparison of their 
clearance rates in human liver microsomes 
Travon Cooman 
 Detection of SCs in body fluids continue to be a challenge because of limited metabolism 
data, lack of standards and reference mass spectrometry data. In vivo and in vitro experiments 
help elucidate metabolite markers for novel psychoactive substances and can prompt synthesis of 
standards to verify proposed metabolites. In this study, metabolism of three SCs N-(1-amino-1-
oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamine (PX-1), N-(1-amino-1-
oxo-3-phenylpropan-2-yl)-1-(5-fluropentyl)-1H-indazole-3-carboxamide (PX-2), and N-(1-
amino-1-oxo-3-phenylpropan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (PX-3) 
were investigated using human liver microsomes. Previous studies showed PX-3 as the most 
potent CB1 and CB2 receptor agonist. 
 Half-life and clearance data were acquired using liquid chromatography- tandem mass 
spectrometry. Metabolite elucidation was performed using liquid chromatography high- 
resolution mass spectrometry in combination with Compound Discoverer®. A previously 
characterized SC, NM2201 was used as a control. 
 The calculated half-lives were 15.1±1.02, 3.4±0.27, 5.2±0.89 minutes for PX-1, PX-2, 
and PX-3 respectively. The calculated intrinsic clearance values were 0.046, 0.202, 0.133 mL/ 
min mg for PX-1, PX-2 and PX-3 respectively. Four metabolites of PX-1, six metabolites of PX-
2 and five phase I metabolites of PX-3 were detected. Oxidative deamination was the common 
biotransformation between the three compounds. Elucidation of marker metabolites are useful to 






 Throughout my life, many people have contributed to my success and this thesis would 
not be possible without their encouragement. 
 First and foremost, thanks to my advisor Dr. Suzanne Bell for first agreeing to accept me 
into her lab and her unwavering support throughout my time as a master’s student. Her 
enthusiasm for science and relaxed personality will always remain with me. She fostered an 
environment that encouraged me to make my own mistakes and learn from them even though 
these mistakes happened sometimes when using expensive analytical instruments. 
 To my committee members Dr. Luis Arroyo and Dr. Jonathan Boyd, I appreciate your 
willingness to mentor me and help me think critically about my research.  
 Thanks to Dr. Glen Jackson who helped me determine structures of MS fragments. 
 A very special thanks to Matthew Maust and Yan Pan for helping me understand how to 
use the necessary instruments and software required to complete this thesis.  
 To Sandra Majuta at WVU Shared Research Facilities, thank you for assisting me with 
troubleshooting the Orbitrap. 
 My colleagues, Tyler Davidson and Bill Feeney, thank you for always listening to me and 
helping me think through challenging problems. 
 My Chicago family, Cindi and Ed Woods, I will forever be grateful to you for your 
support. My mom and dad, although I had to survive without a tasty home cooked meal, you 





Table of Contents 
Abstract ........................................................................................................................................... ii 
Acknowledgments.......................................................................................................................... iii 
Table of Contents ........................................................................................................................... iv 
Table of Figures .............................................................................................................................. v 
List of Abbreviations ..................................................................................................................... vi 
Introduction ..................................................................................................................................... 1 
Literature Review............................................................................................................................ 2 
Materials and Methods .................................................................................................................... 7 
Results and Discussion ................................................................................................................. 11 
Conclusion .................................................................................................................................... 24 
References ..................................................................................................................................... 25 





Table of Figures 
Figure 1: Examples of synthetic cannabinoids in comparison to Δ9 -THC..................................... 4 
Figure 2: Structures of PX1, PX2, PX3 and their analogue. The analogue pairs are: (a) and (d), 
(b) and (e), (c) and (f). .................................................................................................................... 4 
Figure 3: Structural elucidation of metabolites for PX-1, PX-2 and PX-3. .................................. 15 
Figure 4: MS/MS spectra of PX-1 and proposed metabolites. ..................................................... 16 
Figure 5: MS/MS spectra of PX-2 and proposed metabolites. ..................................................... 18 
Figure 6: MS/MS spectra of PX-3 and proposed metabolites. ..................................................... 21 
Figure 7: PX-1and metabolites chromatogram. ............................................................................ 32 
Figure 8: PX-2 and metabolites chromatogram. ........................................................................... 33 
Figure 9: PX-3 and metabolites chromatogram. ........................................................................... 34 
Figure 10: Compound Discoverer Workflow. .............................................................................. 34 
Figure 11: Half-life of PX-1. ........................................................................................................ 35 
Figure 12: Half-life of PX-2. ........................................................................................................ 35 





List of Abbreviations 





CE Collision energy 
Cell Acc Cell accelerator voltage 
CYP Cytochrome P450 
dd Data dependent  






HLM Human liver microsomes 
HPLC High pressure liquid chromatography 
LC/MS Liquid chromatography mass spectrometry 
LOD Limit of Detection 
MRM Multiple reaction monitoring 
MS Mass spectrometry 
NADPH Nicotinamide adenine dinucleotide phosphate 
NM2201 Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate 




PX-1 or 5-fluoro APP-
PICA or SRF-30 
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-
indole-3-carboxamine 
PX-2 or 5- fluoro APP-









SC Synthetic Cannabinoid 














 This thesis is a summary of a manuscript submitted to the Journal of Forensic 
Toxicology in February 2019. 
 New synthetic cannabinoids (SCs) are being constantly introduced into the clandestine 
market to evade detection by law enforcement and researchers. As a result, analytical labs often 
do not have access to reference mass spectra for newer cannabinoids, let alone access to 
reference standards for the parent or metabolites. The extensive metabolism of parent 
compounds make detection in body fluids challenging, but in vitro studies can elucidate marker 
metabolites.  
 The primary goal of this work was to calculate half-life, clearance and to identify 
metabolites to the extent possible of three previously uncharacterized SCs. Human liver 
microsomes, an affordable in vitro alternative for drug biotransformation and pharmacokinetics 
studies was utilized for this purpose. Microsomes are rich in cytochrome P450 (CYP) enzymes 
responsible for the metabolism of most drugs.   
 The three synthetic cannabinoids used in this study, N-(1-amino-1-oxo-3-phenylpropan-
2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamine (PX-1 or 5-fluoro APP-PICA or SRF-30), N-
(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluropentyl)-1H-indazole-3-carboxamide (PX-2 or 5-
fluoro APP-PINACA or FU-PX), and N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide (PX-3 or APP-CHMINACA) were first 
detected in 2015.  
 The structures of the 15 metabolites useful in toxicology analysis were tentatively 
identified using high resolution mass spectrometry (HRMS), whereas half-life and clearance 





 Synthetic Cannabinoids are a class of novel psychoactive substances (NPS) which are 
used for their psychoactive effects [1]. Whenever a NPS is scheduled the structure is easily 
modified so that it goes undetected by Law Enforcement [2]. Toxicologists are faced with the 
challenge of identifying NPS as they have become prevalent [3, 4] and are usually extensively 
metabolized [5]. This makes it difficult to know the parent compound which was consumed. For 
this reason, it is important to study the metabolism of such emerging compounds. Identifying 
marker metabolites can help Forensic Toxicologists propose which NPS might have been 
consumed [6].  
SC Effects 
 Cannabinoid psychotropic effects have been found to be mediated through the G-coupled 
CB1 and CB2 receptors [7]. CB1 receptors are found in neurons of the central nervous system 
whilst CB2 receptors are localized in tissues of the immune system [7]. Cannabinoid 
consumption results in CB1 receptor mediated inhibition of synaptic transmission [8, 9] which 
can lead to mood changes, affecting pain perception, temperature regulation, sleep, and the 
cardiovascular system [10, 11]. This is important because synthetic cannabinoids have been 
shown to have a high affinity for either the CB1 or the CB2 receptors [12, 13] which can prolong 
the effects on consumers. In a survey of 50 patients conducted by Hermanns-Clausen et al. the 
duration of symptoms from synthetic cannabinoids lasted from one hour to more than 24 hours 
[11].  
Classes of SCs 
 SCs were previously classified by structure and were divided into seven major groups: 
naphthoylindoles (e.g. JWH-018), naphthylmethylindoles (e.g. JWH-175), 
naphthylmethylindenes (e.g. JWH-176), naphthoylpyrroles (e.g. JWH-307), phenylacetylindoles 
(e.g. JWH-250), cyclohexylphenols (e.g. CP 47,497), and classical cannabinoids (e.g. HU-210) 
[14]. An example of each class in comparison to Δ9-THC is shown in Figure 1. Constant 
modification of these compounds made this classification system obsolete. Instead of naming 
SCs after the inventor of the compound, researchers now use key components of the structure. 
These components include the core, linker, linked group and tail[15] as shown in Figure 2. Code 
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names can be derived from the chemical names. For example, the code name for N-(1-
adamantyl)-1-pentyl-1H-indole-3-carboxamide is APICA.  
 The SCs used in this study is shown in Figure 2. PX2 has been declared a hazardous or 
illegal substance in Sweden amongst other countries [16]. PX1 and PX2 were declared 
dangerous substances by the Louisiana Legislature in 2015, and was based upon the substances 
high potential for abuse, lack of medical use in the United States, no accepted safety for use 
under medical supervision, and hazard to the health and safety of the Louisiana residents [17]. 
The binding affinity of PX1 is 485±117 and 164±17 nM at the CB1 and CB2 receptors 
respectively[18]. The binding affinity of PX2 is 127±43 and 17.4±1.4 nM at the CB1 and CB2 
receptors respectively[18]. The binding affinity of (S)APP-CHMINACA at the CB1 receptor is 
251 nM and 8.09 nM at the CB2 receptor with a selective index of 31.0 [19]. Doi et al reported 
the binding affinity of (R)APP-CHMINACA as 33.7 µM and 190 nM at the CB1 and CB2 
receptors respectively, with a selective index of 68.8 making (S)APP-CHMINACA more potent.  
 As shown in Figure 2, although similar in structure, PX1 has an indole core whereas PX2 
has an indazole core. Similar to PX2, PX3 has an indazole core but a cyclohexylmethyl tail. 
These differences are enough for each to be categorized separately. The PINACA class has an n-
pentyl tail, indazole core, carboxamide linker but varying linked groups. The CHMINACA class 
has a cyclohexylmethyl tail, indazole core, carboxamide linker but varying linked groups. PICA 












Models for Metabolite Identification  
 In vitro studies which elucidate marker metabolites have been performed using human 
liver microsomes and hepatocytes [20]. Hepatocytes contain uptake and efflux transporters for 
the movement of drugs across cell membranes [21] and the necessary enzymes and co-factors for 
drug metabolism in concentrations similar to the liver, thereby close to in vivo conditions [22]. 
However, they are expensive, not readily available, preparations can only be used once[22, 23], 
and they have limited viability [24]. Human liver microsomes offer an affordable alternative. It is 
a well characterized in vitro model which retains enzyme activity for many years when frozen at 
−80℃ [24]. Drug biotransformation and pharmacokinetics data such as half-life and clearance 
can be derived from microsomal models [25],[26]. The time taken for the concentration of a drug 
to decrease by half is called its half-life. Intrinsic clearance is the assessment of the liver’s 
activity towards a drug and can be used to confirm metabolism as the major route of drug 
clearance [27, 28]. Microsomal clearance can be scaled to calculate liver and hepatic clearance 
thereby increasing understanding of in vivo conditions. Although half-life and clearance are 
important parameters used for drug discovery and dosing regimens, they are equally useful in 
forensic testing as they can indicate if the parent drug or metabolite is a better proposition for 
drug consumption. A drug’s structure can be useful in determining the extent of metabolism. 
Studies have shown that lipophilic drugs have greater clearance and therefore undergo extensive 
first pass metabolism [29–31],[32]. 
 Drug metabolizing enzymes are classified as phase I and phase II. Phase I enzymes 
consist of the cytochrome P450 (CYP) superfamily of microsomal enzymes found in the liver, 
lungs, kidneys and gastrointestinal tract [33] and play a crucial role in drug metabolism [34]. 
Phase II enzymes include sulfotransferases [35], UDP-glucoronosyltransferases, epoxide 
hydrolases, glutathione S-transferases and N-acetyltransferases among others. Drugs are 
generally conjugated during phase II metabolism and are made more hydrophilic to enhance 
excretion in urine [33]. During phase I, drugs are modified through hydrolysis, oxidation, and 
reduction [20] therefore enabling further conjugation during phase II. Although microsomes lack 
phase II enzymes, they are rich in cytochrome P450 (CYP) enzymes [36],[37],[38]. This enables 
the detection of metabolites prior conjugation in phase II.  
 In silico studies may be conducted to predict metabolites of uncharacterized novel 
psychoactive substances. A knowledge of the solubility of the drug can help predict how it 
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interacts with other molecules in a particular environment and therefore the transformations it 
may undergo [39]. In this study Compound Discoverer® was used to elucidate metabolism 






Materials and Methods 
 PX-1, PX-2, PX-3, NM2201, 5FPB22 metabolite, PB-22-d9, standards purchased from 
Cayman Chemical Company® (Ann Arbor, Michigan). NADPH Regenerating System solution A 
and B, and 0.5 M potassium phosphate buffer, pH 7.4 purchased from Corning® (Woburn, MA). 
HPLC grade methanol, acetonitrile with 0.1% formic acid as solvent B and water in 0.1% formic 
acid as solvent A purchased from Fisher Chemical® (Fair Lawn, New Jersey). Thermo Scientific 
Hypersil GOLD C18 column (30 mm x 2.1 mm x 3 µm), guard column holder and 5 µm drop-in 
guard cartridges, human liver microsomes (20 mg/mL) purchased from Thermo Scientific®. 
Method Validation 
 Bias, calibration, carryover, ionization suppression and enhancement, precision were 
evaluated using SWGTOX guidelines [40]. Limit of detection was estimated using equation 1. 
𝐿𝑂𝐷 =




All compounds were optimized and analyzed on an Agilent 6470A Triple Quadrupole LC/MS 
(Agilent Technologies) coupled with a 1290 Infinity II LC system (Agilent Technologies). The 
method parameters are listed in Supplementary Table 1 (Appendix 1) and the transitions in Table 
1.   The cell accelerator voltage was 4 V. The calibrators included 5.0, 10.0, 25.0, 50.0, and 
100.0 ng/mL and were prepared in blank matrix which comprised of 0.5 M potassium phosphate 
buffer pH 7.4, deionized water, and acetonitrile. The low, medium and high controls were 10.0 
ng/mL, 50.0 ng/mL and 100.0 ng/mL respectively. Each sample was spiked with 25.0 ng/mL 












Table 1: Compound transitions. 
Compound Precursor Ion Product Ion Frag (V) CE (V) 
5FPB22 met 250.1 
206.2 90 15 
132.1 90 25 
118.1 90 25 
NM2201 376.2 
232.0 55 12 
144.0 55 48 
115.9 55 72 
PB22d9 368.2 
223.1 68 12 
145.0 68 48 
117.0 68 72 
PX-1 396.2 
232.0 70 20 
144.0 70 52 
116.0 70 76 
PX-2 397.2 
233.0 75 24 
213.0 75 40 
145.0 75 50 
PX-3 405.2 
360.1 85 16 
241.0 85 28 
145.0 85 48 
 
Metabolite Identification 
 Microsome incubation procedure was adapted from previous studies[41]. The HLM 
suspension was thawed at 37℃. The reaction mixture contained 780 µL distilled water, 100 µL 
0.5 M potassium phosphate buffer pH 7.4, 10 µL solution B, 10 µL 100.0 µmol/L drug, 50 µL 
HLM suspension, and 50 µL solution A to initiate the reaction. NM2201 was used as a positive 
control and the metabolite1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5FPB22) was 
monitored as previously studied [42]. All samples were incubated at 37℃. Aliquots of 500 µL 
were collected at 0, and 60 minutes and was quenched with 500 µL ice-cold acetonitrile. The 
samples were centrifuged at 10,000 rpm for 5 minutes. The supernatant was dried under nitrogen 
gas at 50℃ and reconstituted with 300 µL methanol and acetonitrile (50:50). Samples were 
analyzed using a Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (ThermoFisher 
Scientific®) coupled with a PAL HTC Accelera autosampler and Accelera 1250 pump. The 
gradient system was as follows: 10% B until 0.6 minutes and held until 10.5 minutes, ramped to 
95% B and held until 11.0 minutes, ramped down to 10% B and held until 13.0 minutes. The 
flow rate was 500 µL/min. 
 Data was acquired using Full MS and ddMS2 using the optimized parameters in Table 2. 
Compound Discoverer v2.1.0.401 (ThermoFisher Scientific®) was used for elucidation of 
metabolite profiling and Thermo XCalibur™ v2.2 (ThermoFisher Scientific®) to verify mass 
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spectra. The workflow from Compound Discoverer is shown in Appendix 1. The phase I 
transformations for NM2201, PX-1 and PX-2 included dehydration, desaturation, hydration, 
nitro reduction, oxidation, oxidative deamination to alcohol and ketone, oxidative defluorination, 
reduction, and reductive defluorination whereas no fluorine transformations were selected for 
PX-3 as it has no fluorine in its structure. Glucuronide conjugation was the only phase II 
transformation assessed. Dealkylation and dearylation were applied for a maximum of two steps 
utilizing a minimum mass of 150 Da. Mass tolerance was set to 5 ppm. The experiment was 
duplicated. 
 
Table 2: Q- Exactive Full MS/ dd-MS2 properties used for metabolite identification. 
General  
Runtime 0 to 13 min 
Polarity positive 
Default charge 2 
Full MS  
Resolution 70,000 
AGC target 1e6 
Maximum IT 200 ms 
Scan range 100 to 600 m/z 
dd-MS2/ dd-SIM  
Resolution 35,000 
AGC target 1e5 
Maximum IT 50 ms 
Loop count 5 
TopN 5 
Isolation window 2.0 m/z 
(N)CE/ stepped nce 35 
dd Settings  
Minimum AGC target 1e3 
Intensity threshold 2e4 
Exclude isotope on 
Dynamic exclusion 10.0 s 
 
Metabolic Stability using HLM 
 The incubation procedure was similar to the metabolite identification procedure described 
above but aliquots of 100 µL were collected at 0, 3, 8, 13, 20, 45, and 60 minutes after the 
reaction has been initiated. The supernatant was spiked with 10 µL of 25 ng/mL internal standard 
and analyzed using dynamic MRM on an Agilent 6470A Triple Quadrupole LC/MS (Agilent 
Technologies) coupled with a 1290 Infinity II LC system (Agilent Technologies). A linear 
gradient elution was used (Supplementary Table 1). Sample volume injected was 2 µL. The 
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autosampler temperature was kept at 5℃. The gas temperature set to 325℃; gas flow to 5 L/min; 
nebulizer to 45 psi; sheath gas temperature to 350℃; sheath gas flow to 11 L/min; capillary 
voltage to 3500 V; and nozzle voltage to 500 V. 
 Data analysis performed using MassHunter B.08.00 (Agilent Technologies). The 
quantitative transitions were 250.1→ 206.2, 376.2→ 232.0, 368.2→ 223.1, 396.2→ 232.0, 
397.2→ 233.0, 405.2→ 241.0 for 5FPB22 metabolite, NM2201, PB229, PX-1, PX-2 and PX-3 
respectively. Optimization parameters for each compound is shown in Table 1. Half-life and 






Results and Discussion 
Method Validation 
 Bias was less than ±20% for all compounds. All analytes were within ±20% ionization 
suppression/enhancement at 25.0 ng/mL and 100.0 ng/mL except 5FPB22 metabolite which was 
27% at low range and 23% at the high range. This was acceptable as 5FPB22 metabolite was 
used qualitatively. The correlation coefficient for within and between injection variability were 
0.999 and 1.000 for all analytes respectively. Between-run and within-run %CV were within 
±10%. The estimated LOD was 0.4, 0.6, 0.3, 0.3, and 1.8 ppb for PX-1, PX-2, PX-3, NM2201, 
and 5FPB22 metabolite respectively. No carryover was observed. 
Metabolic Stability 
 Clearance was determined using the natural logarithm of the drug/ internal standard ratio. 
Equation 2 was used to calculate half-life values. k was calculated from the slope of the time vs 
LN (drug/ internal standard) ratio. Clearance was calculated using equation 3 adapted from 






















where [V ] is the incubation volume in mL and [P] is the amount of microsomal protein in 
the incubation. Table 3 summarizes the half-life and clearance data. The half-life of the control, 
naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (NM2201) was 6.7 ± 0.75 minutes 
and intrinsic clearance, 0.103 mL/min/mg. Diao et al reported a half-life value of 8.0 ± 1.5 
minutes and in vitro clearance as 0.088 mL/min/mg for NM2201 [42]. The calculated half-lives 
for PX-1, PX-2 and PX-3 were 15.1 ± 1.02, 3.4 ± 0.27, and 5.2 ± 0.89 respectively as shown in 
Table 3. Plots of the half-life data is shown in Appendix 1. PX-1 showed the lowest clearance 
rate, 0.046 mL/min/mg whereas PX-2 had the highest clearance rate, 0.202 mL/min/mg. Drugs 
may be excreted in urine unchanged or chemically modified to facilitate excretion. In this study, 
a higher clearance rate was expected for the more polar PX-1 but the lack of phase II enzymes 
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may have limited clearance. PX-2 and PX-1 were expected to have comparable clearance rates 
due to structural similarities. The difference in the observed values may have been due to an 
extra nitrogen atom in PX-2 which made it less polar, but sufficiently metabolized by CYP450 
enzymes to facilitate excretion. However, the results indicate that the SCs are all extensively 
metabolized. 
 A survey of the literature yielded binding affinities, clearance and half- life data for SCs 
structurally similar to the ones investigated in this study (Table 3). In this study, PX-1, PX-2 and 
PX-3 were compared to other PICA, PINACA and CHMINACA SCs respectively, where the 
only difference was the linked group. Although there is limited half-life and clearance data, PX-1 
showed the lowest clearance rate in the PICA class and was the least potent based on Ki values. 
It is possible the phenylalaninamide component of PX-1 increases its polarity more than 5F-
CUMYLPICA and STS-135 which require higher clearance. However, further investigations for 
amide containing PICA SCs such as 5F-ADBICA, 5F-AB-PICA and 5F-SDB-006 are required 
to support these observations. Although PX-2 is the least potent PINACA, it is not the least 
cleared. A similar trend to PX-1 is expected but would require further investigations. No data 
was available for other CHMINACA SCs, but low polarity compounds may show higher 
clearance in vitro. A class comparison of half-life and clearance data can provide useful 
















Table 3: Half-life, clearance and Ki summary for selective SC structurally related to PX-1, PX-2, PX-3. 
Drug 𝑻𝟏
𝟐
 (mins) 𝑪𝒍𝒊𝒏𝒕,𝒎𝒊𝒄𝒓 (mL/min/mg) Ki at CB1 (nM) Ki at CB2 (nM) 
PICA 
5F-CUMYL-PICA 1.77[43]  0.39[43]  1.37 ± 0.26[18] 29.1 ± 2.4[18] 
STS-135 3.1 ± 0.2[44]  0.222[44]  2.51 ± 0.35[45] 0.794 ± 0.071[45] 
5F-ADBICA N/A N/A 2.72 ± 0.35[18] 1.83 ± 0.11[18] 
5F-MDMB-PICA N/A N/A 9.35 ± 0.07[46] 8.13 ± 0.05[46] 
5F-MMB-PICA N/A N/A 15.2 ± 5.0[18] 19.8 ± 4.2[18] 
5F-AB-PICA N/A N/A 35 ± 7.7[18] 89.0 ± 33.2[18] 
5F-SDB-006 N/A N/A 71.9 ± 13.5[45] 430 ± 73[45] 
PX-1 (APP-PICA) 15.1 ± 1.02 0.046 485 ± 117[18] 164 ± 17[18] 
PINACA 
5F-AMB 1.0 ± 0.2[47] 0.67[47] 1.13 ± 0.48[18] 1.38 ± 0.22[18] 
5F-ADB-PINACA N/A N/A 1.43 ± 0.69[18] 0.694 ± 0.078[18] 
5F-APINACA N/A N/A 1.94 ± 0.55[45] 0.266 ± 0.041[45] 
5F-AB-PINACA 35.9 ± 3.0[48]  0.019[48] 4.96 ± 1.37[18] 3.77 ± 0.25[18] 
5F-ADB N/A N/A 23.3 ± 10.2[18] 5.99 ± 2.47[18] 
PX-2 (APP-
PINACA) 




N/A N/A 0.135 ± 0.028[18] 0.222 ± 0.034[18] 
MAB-CHMINACA N/A N/A 0.333 ± 0.059[18] 0.331 ± 0.048[18] 
MA-CHMINACA N/A N/A 0.339 ± 0.073[18] 0.301 ± 0.092[18] 
AB-CHMINACA N/A N/A 1.72 ± 0.14[18] 
0.78 ± 0.11[49] 
1.91 ± 0.20[18] 
0.45 ± 0.03[49] 
PX-3 (APP-
CHMINACA) 
5.2 ± 0.89 0.133 (R) 33.7 µM[19] 
(S) 251[19] 
9.81 ± 4.56[18] 
(R) 190[19] 
(S) 8.09[19] 







Metabolite Identification  
 
PX-1 Metabolic Pathway 
 The four proposed phase I metabolites of PX-1 in this study, are shown in Figure 3. 
Oxidation was the common route of biotransformation for all PX-1 metabolites. SRF-3 ((1-(5-
fluoropentyl)-1H-indole-3-carbonyl)phenylalanine), was the only fluorinated metabolite detected 
and eluted later than PX-1 despite containing more oxygen atoms. Although metabolites are 
usually more hydrophilic than parent compounds to facilitate excretion, in this study less polar 
metabolites were observed possibly because phase II enzymes were lacking. The clearance rate 
of PX-1 suggest conjugation as a dominant biotransformation pathway. A summary of the 
retention times and diagnostic ions is shown in Table 4 and chromatograms are shown in 
Appendix 1. 
 As shown in Figure 4, the base peak from SRF-1 and SRF-4 at m/z 230.1180 is a loss of 
phenylalaninamide (C9H12N2O, 164.0949 Da) and phenylalanine (C9H11NO2, 165.0793 Da) 
respectively. A similar loss for PX-1 and SRF-3 showed the same characteristic ion at m/z 
232.1137 ± 0.0001 because they contain fluorine. PX-1 and its metabolites all yielded the 
characteristic ion at m/z 144.0446 ± 0.0002 which corresponds to a loss of either the fluoropentyl 






































































PX-2 Metabolic Pathway 
 Figure 3 shows six proposed metabolites of PX-2 from this study. Oxidation was the 
major route of biotransformation. Four fluorinated metabolites FU-1 ((1-(5-fluoropentyl)-1H-
indazole-3-carbonyl)phenylalanine), 4, 5 and 6 were observed but FU-4/5/6 eluted before FU-1 
due to the presence of the extra hydroxyl group on the indazole core, as confirmed by the 
retention times in Table 5. Chromatograms of PX-2 and metabolites are shown in Appendix 1.  
 PX-2 and the major metabolite FU-1 shared the same diagnostic ions as shown in Figure 
5. Although a fragmentation pattern similar to PX-1 was expected, the possible rearrangement of 
PX-2 and FU-1 resulted in the base peak at m/z 251.1194. The diagnostic ion at m/z 233.1088 ± 
0.0001, common to PX-2, FU-1, FU-5 and FU-6 is consistent with the loss of phenylalaninamide 
or phenylalanine in addition to the loss of OH for FU-5 and FU-6. The characteristic ion at m/z 
213.1025 ± 0.0002 which corresponds to C13H13N2O
+, was common to all metabolites of PX-2 
but FU-4. Another commonly observed characteristic ion was m/z 145.0399 ± 0.0001 
(C8H5N2O
+). 
 The hydroxylation of FU-1 on the indazole core resulted in the isomer metabolites FU-4, 
FU-5, and FU-6 with molecular ion m/z 414.1829. The characteristic ion at m/z 267.1143 ± 
0.0001 is a possible rearrangement of the phenyl methyl group on the indazole core. The ion at 
m/z 249.1037 (C13H14FN2O2
+) for FU-4 (Figure 5) indicates the hydroxyl group is on the 




Additional evidence is provided by the observation of fragments at m/z 161.0348 (C8H5N2O2
+) 
and m/z 229.0975 (C13H13N2O2
+). However, confirmation of the proposed metabolites would 
require standards which were not available.  
 
































































































   
PX-3 Metabolic Pathway 
 Figure 3 shows five detected metabolites of PX-3. The major metabolite APP-1 ((1-
(cyclohexylmethyl)-1H-indazole-3-carbonyl)phenylalanine), was formed from the deamination 
of PX-3. Unlike PX-1 and PX-2, fluorine is absent in PX-3 but the cyclohexyl methyl group has 
a similar effect on its hydrophilicity. As shown by the retention times in Table 6, APP-1 was 
least polar whereas the hydroxylated metabolites eluted first. Appendix 1 shows the 
chromatogram of PX-3 and metabolites. 
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 PX-3 and APP-1, have similar MS/MS spectra. The diagnostic ion m/z 360.2073 for PX-
3, shown in Figure 6 is a loss of CH3NO, 45.0220 Da whereas the same ion is a loss of CH3O2, 
46.0057 Da for APP-1. The base peak m/z 241.1340 for both compounds resulted from the loss 
of phenylalaninamide and phenylalanine for PX-3 and APP-1 respectively. Subsequent loss of 
methylenecyclohexane, C7H12, 96.0939 Da resulted in m/z 145.0399 also observed in metabolites 
of PX-2. A noteworthy fragment, m/z 259.1444 differs from m/z 360.2077 by 101.0633 Da and 
from m/z 241.1338 by 18.0106 Da. Analysis of standards would help explain these observations. 
 The minor metabolites APP-2/3/4/5 ((1-((hydroxycyclohexylmethyl)methyl)-1H-
indazole-3-carbonyl)phenylalanine) are isomers which came from the hydroxylation of 
cyclohexane on APP-1. Figure 6 shows the observed MS/MS spectrum was the same for each 
isomer. Diagnostic ion m/z 404.1974 is from the dehydration of molecular ion m/z 422.2081. 
Subsequent loss of CH2O2, 46.0061 Da resulted in m/z 358.1913. Loss of phenylalanine, 
165.0793 Da from the molecular ion resulted in the base peak, m/z 257.1288. Subsequent 






























































































Suggested marker metabolites  
 SRF-1 can be considered a marker metabolite because it was the most abundant PX-1 
metabolite and is sufficiently polar. SRF-2, the second most abundant metabolite of PX-1 is a 
good target because it was the most polar of the detected metabolites. FU-1 and APP-1 were the 
major metabolites of PX-2 and PX-3 respectively, and while good marker metabolites further 
transformation may occur to increase elimination. FU-2 and APP-2 are also likely marker 
metabolites which may be detected in urine. The detected metabolites for the targeted 
compounds did not overlap with each other’s proposed metabolic pathway or previously 
characterized SCs of the same class. However, similarities in diagnostic ions were observed. 
Two common fragments m/z 144 and m/z 232 observed in PX-1 and similar PICA SCs are 
characteristic of the indole core and fluoropentyl tail [43, 44, 50]. The fragments m/z 145, 233, 
and 213 were observed in the elucidation of PX-2 and other PINACA compounds and are 
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characteristic of the indazole core and fluoropentyl tail [47, 48, 51, 52]. The most common 
fragments m/z 145, 257, and 241 observed in PX-3 and other CHMINACA SCs are characteristic 
of the indazole core and cyclohexylmethyl tail. These observations suggest fragments 
corresponding to the core of SCs may be insufficient for confirmation and therefore require 






 Potent synthetic cannabinoids are constantly emerging on the black market. Studies have 
shown these substances to undergo extensive biotransformation thus making parent compounds 
challenging to detect by existing methods. However, in vitro studies are useful in identifying 
potential marker metabolites. 
 The observations in this study suggest the metabolic pathways of PX-1, PX-2 and PX-3 
do not overlap. Four, six, and five metabolites of PX-1, PX-2 and PX-3 respectively, were 
detected and their structures elucidated. Oxidation was the common biotransformation between 
compounds and the major metabolite of PX-1 was transformed through oxidative defluorination 
whereas PX-2 and PX-3, through oxidative deamination. SRF-1, SRF-2, FU-1, FU-2, APP-1 and 
APP-2 are promising marker metabolites. This work showed PX-1 had the highest half-life (15.1 
± 1.02 mins) and subsequently the lowest clearance (0.046 mL/min/mg) whereas PX-2 had the 
highest clearance (0.202 mL/min/mg). Comparison of available clearance data for similar 
compounds indicate functional groups which reduce polarity have higher clearance rates, but 
further research is required to support this hypothesis. Standards for marker metabolites and in 
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Supplementary Table 1: Agilent 6470A LC method properties 
Time (mins) A % B % Flow(mL/min) 
0.0 90.0 10 0.3 
0.6 90.0 10.0 0.3 
1.5 85.0 15.0 0.3 
2.0 80.0 20.0 0.3 
2.5 70.0 30.0 0.3 
3.0 65.0 35.0 0.3 
3.5 60.0 40.0 0.3 
4.0 55.0 45.0 0.3 
4.5 52.5 47.5 0.3 
5.0 50.0 50.0 0.3 
5.5 45.0 55.0 0.3 
5.75 42.5 57.5 0.3 
5.85 41.5 58.5 0.3 
6.0 40.0 60.0 0.3 
6.5 35.0 65.0 0.3 
8.5 20.0 80.0 0.3 
10.5 5.0 95.0 0.3 
















Figure 9: PX-3 and metabolites chromatogram. 
 




Figure 11: Half-life of PX-1. 
 




Figure 13: Half-life of PX-3. 
 
 
